Taysha Q3 Loss Widens to $39.1M; $422.8M Cash Funds Runway Into 2H 2028
TSHA sits 22% above its 52-week low of $3.455.
Summary
Taysha's Q3 2026 net loss widened to $39.1M as R&D spending scaled for its pivotal Rett program, but $422.8M in cash is projected to fund operations into the second half of 2028. The REVEAL pivotal 6-month interim data and FDA feedback are expected in the first half of 2027.
Key Events · Earnings and Guidance · TSHA
-
Q3 Loss Widens on R&D Scale-Up
Net loss was $39.1M for Q3 2026 versus $32.7M a year earlier; nine-month net loss reached $128.2M versus $81.1M.
-
R&D Spend Jumps on BLA Manufacturing
Research and development expense was $101.2M for the nine months ended September 30, 2026, up from $61.5M, driven by BLA-enabling PPQ manufacturing and the REVEAL Part A, REVEAL pivotal and ASPIRE trials.
-
Cash Runway Into Second Half 2028
Cash and cash equivalents stood at $422.8M at September 30, 2026, which management believes funds planned operations into the second half of 2028.
-
Pivotal Data Expected First Half 2027
All 17 patients in the REVEAL pivotal trial are dosed; the 6-month interim analysis topline data and FDA regulatory feedback are anticipated in the first half of 2027.
Analysis · TSHA · Life Sciences
Taysha's cost base stepped up this quarter as the company funded BLA-enabling manufacturing and its pivotal Rett syndrome trials. R&D ran $101.2M for the nine months versus $61.5M a year earlier, pushing the nine-month net loss to $128.2M from $81.1M. Against that burn, the June 2026 offering left $422.8M of cash, which management says funds operations into the second half of 2028, so there is no near-term financing pressure ahead of the REVEAL pivotal 6-month interim analysis. That readout, plus FDA feedback, is expected in the first half of 2027 and is the event that will determine whether the BLA path holds. The completed PPQ campaign and the planned Q4 2026 FDA CMC meeting remove a manufacturing gating item, and the terminated Durham lease trimmed facility costs while adding a $3.4M one-time gain.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TSHA was trading at $4.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $3.46 to $7.30. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.